The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Growth In Market Value Is Anticipated For The Cardiovascular Genetic Testing Market Between 2026 And 2030?

The market for cardiovascular genetic testing has experienced significant growth over the past few years. It is anticipated to expand from $3.93 billion in 2025 to $4.35 billion in 2026, at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the past can be attributed to heightened awareness of inherited cardiovascular disorders, the broadening of molecular diagnostic capabilities, decreasing costs associated with genetic sequencing, an increase in the use of genetic counseling services, and more research in cardiovascular genomics.

The cardiovascular genetic testing market is set to experience substantial growth in the upcoming years, projected to reach $6.62 billion in 2030 with a compound annual growth rate (CAGR) of 11.0%. This expansion over the forecast period is driven by factors such as the increasing need for precision medicine approaches, a rise in the adoption of population-based genetic screening, the broader application of AI-driven variant interpretation, the growing integration of genomics into clinical decision making, and an increased focus on preventive cardiovascular healthcare. Significant trends expected during this period include the wider acceptance of predictive genetic risk assessment, a surge in the use of multigene panel testing, the deeper integration of bioinformatics and AI analytics, the expansion of pharmacogenomic testing applications, and an enhanced emphasis on personalized cardiovascular care.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=33054&type=smp

What Important Drivers Are Powering The Cardiovascular Genetic Testing Market Growth?

The increasing incidence of cardiovascular diseases is projected to drive the expansion of the cardiovascular genetic testing market moving forward. Cardiovascular diseases, or CVDs, encompass a range of conditions affecting the heart and blood vessels, such as heart attacks, strokes, and hypertension. The rise in cardiovascular disease prevalence is primarily attributed to increasingly sedentary lifestyles linked to urbanization, which foster obesity, high blood pressure, and metabolic disorders. This growing frequency of cardiovascular diseases stimulates demand for genetic testing, as early detection of genetic predispositions enables personalized prevention and treatment strategies to mitigate the risk of serious heart issues. For instance, in January 2024, the American Heart Association, a US-based non-profit organization, reported that the age-adjusted death rate from cardiovascular disease reached 233.3 per 100,000 in 2024, indicating a 4.0% increase from 224.4 per 100,000 in 2023. Consequently, the rising prevalence of cardiovascular disease is a significant force propelling the growth of the cardiovascular genetic testing market.

Which Segment Groups Define The Cardiovascular Genetic Testing Market Landscape?

The cardiovascular genetic testing market covered in this report is segmented –

1) By Testing Type: Predictive Testing; Carrier Testing; Prenatal And Newborn Testing; Diagnostic Testing; Pharmacogenomic Testing; Other Testing Types

2) By Disease: Inherited Cardiomyopathies; Hypertrophic Cardiomyopathy (HCM); Dilated Cardiomyopathy (DCM); Arrhythmia; Aortopathies; Other Diseases

3) By Technology: Cytogenetic Testing; Biochemical Testing; Molecular Testing

4) By Application: Chromosome Analysis; Genetic Disease Diagnosis; Cardiovascular Disease Diagnosis; Other Applications

5) By End User: Hospitals And Clinics; Diagnostic Laboratories; Research Institutions; Genetic Counseling Centers; Pharmaceutical Companies; Direct-To-Consumer Testing

Subsegments:

1) By Predictive Testing: Presymptomatic Risk Assessment; Familial Variant Screening; Polygenic Risk Evaluation; Late Onset Disease Prediction; Susceptibility Gene Testing

2) By Carrier Testing: Autosomal Recessive Carrier Screening; Linked Carrier Screening; Expanded Carrier Screening Panels; Single Gene Carrier Screening; Family History Based Carrier Testing

3) By Prenatal And Newborn Testing: Non Invasive Prenatal Genetic Testing; Invasive Prenatal Diagnostic Testing; Newborn Metabolic Screening; Congenital Heart Disease Genetic Screening; Neonatal Gene Panel Testing

4) By Diagnostic Testing: Single Gene Diagnostic Testing; Multigene Panel Diagnostic Testing; Whole Exome Diagnostic Testing; Whole Genome Diagnostic Testing; Variant Confirmation Testing

5) By Pharmacogenomic Testing: Drug Response Gene Testing; Adverse Drug Reaction Risk Testing; Dose Optimization Genetic Testing; Anticoagulant Response Testing; Cardiovascular Drug Metabolism Testing

6) By Other Testing Types: Cascade Family Testing; Population Based Genetic Screening; Research Use Genetic Testing; Confirmatory Follow Up Testing; Clinical Trial Genetic Testing

What Trends Are Influencing The Cardiovascular Genetic Testing Market Outlook?

Leading companies in the cardiovascular genetic testing market are concentrating on developing innovative solutions, such as clinician-ordered tests, to ensure medical necessity and tailor them to a patient’s specific health condition, thereby reducing redundant testing and costs. A clinician-ordered test is defined as a medical examination or diagnostic procedure requested by a healthcare professional to assess, monitor, or guide the management of an individual’s health status. For instance, in September 2025, Mass General Brigham, a US-based not-for-profit integrated academic healthcare system, in collaboration with Broad Clinical Labs, a US-based genomic data generation laboratory, and Mass General Brigham Laboratory for Molecular Medicine, a US-based molecular diagnostic laboratory, introduced a genetic test designed to evaluate inherited risk for eight cardiovascular conditions. This clinician-ordered test is offered on a self-pay basis and assesses genetic predisposition to eight conditions, which include atrial fibrillation, coronary artery disease, type 2 diabetes, elevated lipoprotein(a), hypercholesterolemia, hypertension, thoracic aortic aneurysm, and venous thromboembolism. Its development incorporated genotype and clinical data from 236,393 participants in the NIH’s All of Us Research Program. Publicly available polygenic risk scores for each condition were integrated utilizing PRSmix, an elastic-net modeling approach that combines multiple component scores into a single, comprehensive risk score per disease. High-resolution genetic data is captured through a clinical blended genome-exome assay at Broad Clinical Labs, while the CLIA-certified Mass General Brigham Laboratory for Molecular Medicine is responsible for interpreting the results and generating patient-friendly reports.

Which Firms Are Competing In The Cardiovascular Genetic Testing Market?

Major companies operating in the cardiovascular genetic testing market are Labcorp Holdings Inc., Quest Diagnostics Inc., ICON plc, Illumina Inc., Apollo Hospitals, OPKO Health Inc., Revvity Inc., ARUP Laboratories Inc., Mayo Clinic Laboratories, Fulgent Genetics Inc., MedGenome Inc., Genome Medical, PreventionGenetics, Eurofins Genomics LLC, Blueprint Genetics Inc., MapmyGenome, GENinCode, Allelica Srl, Rocket Pharma Inc., and Health in Code SL.

Access The Complete Cardiovascular Genetic Testing Market Report:

https://www.thebusinessresearchcompany.com/report/cardiovascular-genetic-testing-market-report

What Is The Largest Regional Market In The Cardiovascular Genetic Testing Market?

North America was the largest region in the cardiovascular genetic testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiovascular genetic testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access a Customized Cardiovascular Genetic Testing Market Report for Deeper Competitive Insights

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model